Skip to main content

Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer

Medical Oncology volume 29, pages 3394–3399 (2012)Cite this article

Abstract

Cervical cancer remains one of the most common malignancies in women. Previous study proved MMP-9 might be prognostic marker for multiple human malignancies. The present study was to investigate the protein expression of MMP-9 in cervical cancer and its association with clinicopathological characteristics as well as prognosis of patients. Cervical cancer specimens from 225 cases who had not received chemotherapy or radiotherapy prior to surgery were collected. Immunochemistry assays were utilized to investigate MMP-9 protein expression. Results showed that MMP-9 expression was increased in cervical cancer and associated with stromal invasion, FIGO stage, lymph node metastasis, and vascular invasion. Kaplan–Meier analysis showed that patients with cervical cancer of positive MMP-9 staining tend to have worse overall survival. In multivariate analysis stratified for known prognostic variables, MMP-9 was proved to be an independent prognostic factor. The present study confirmed that MMP-9 expression in cervical cancer was an independent prognostic factor of patients, which might be a potential diagnostic and even therapeutic target of cervical cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    PubMed  Article  Google Scholar 

  2. Waggoner SE. Cervical cancer. Lancet. 2003;361:2217–25.

    PubMed  Article  Google Scholar 

  3. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.

    PubMed  Article  Google Scholar 

  4. Janicek MF, Averette HE. Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin. 2001;51:92–114.

    PubMed  Article  CAS  Google Scholar 

  5. Kim CH, Abu-Rustum NR, Chi DS, et al. Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer. Gynecol Oncol. 2012;125:585–8.

    PubMed  Article  CAS  Google Scholar 

  6. Kim TE, Park BJ, Kwack HS, et al. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation. J Obstet Gynaecol Res. 2012. doi:10.1111/j.1447-0756.2012.01871.

  7. Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012;125:343–5.

    PubMed  Article  Google Scholar 

  8. Sobel G, Szabó I, Páska C, et al. Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia. Pathol Oncol Res. 2005;11:26–31.

    PubMed  Article  CAS  Google Scholar 

  9. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300–8.

    PubMed  Article  CAS  Google Scholar 

  10. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev Cancer Metastasis Rev. 1990;9:289–303.

    Article  CAS  Google Scholar 

  11. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284:67–8.

    PubMed  Article  CAS  Google Scholar 

  12. Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases. Br J Surg. 1997;84:160–6.

    PubMed  Article  CAS  Google Scholar 

  13. Curran S, Murray GI. Matrix metalloprteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621–30.

    PubMed  Article  CAS  Google Scholar 

  14. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–4.

    PubMed  Article  CAS  Google Scholar 

  15. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–49.

    PubMed  CAS  Google Scholar 

  16. Aalinkeel R, Nair BB, Reynolds JL, et al. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest. 2011;40:447–64.

    PubMed  Article  CAS  Google Scholar 

  17. Kumar B, Koul S, Petersen J, et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res. 2010;70:832–41.

    PubMed  Article  CAS  Google Scholar 

  18. Joergensen MT, Brünner N, De Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res. 2010;30:587–92.

    PubMed  CAS  Google Scholar 

  19. Servais EL, Colovos C, Rodriguez L, et al. Mesothelin overexpression promotes mesothelioma cell invasion and mmp-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012;18:2478–89.

    PubMed  Article  CAS  Google Scholar 

  20. Yang B, Su K, Gao J, Rao Z. Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer. Asian Pac J Cancer Prev. 2012;13:1049–52.

    PubMed  Article  Google Scholar 

  21. Choi JY, Jang YS, Min SY, et al. Overexpression of MMP-9 and HIF-1α in breast cancer cells under hypoxic conditions. J Breast Cancer. 2011;14:88–95.

    PubMed  Article  Google Scholar 

  22. Choe G, Park JK, Jouben-Steele L, et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002;8:2894–901.

    PubMed  CAS  Google Scholar 

  23. Kang H, Jang SW, Ko J. Human leucine zipper protein sLZIP induces migration and invasion of cervical cancer cells via expression of matrix metalloproteinase-9. J Biol Chem. 2011;286:42072–81.

    PubMed  Article  CAS  Google Scholar 

  24. Schröer N, Pahne J, Walch B, et al. Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res. 2011;71:87–97.

    PubMed  Article  Google Scholar 

  25. Ng KT, Qi X, Kong KL, et al. Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. Eur J Cancer. 2011;47:2299–305.

    PubMed  Article  CAS  Google Scholar 

  26. Chen T, Zhu J. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 2010;27:1185–91.

    PubMed  Article  CAS  Google Scholar 

  27. Buergy D, Weber T, Maurer GD, et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer. 2009;125:894–901.

    PubMed  Article  CAS  Google Scholar 

  28. Wu W, Wang R, Liu H, et al. Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry. Med Oncol. 2009;26:117–23.

    PubMed  Article  CAS  Google Scholar 

  29. Lai HC, Chu CM, Lin YW, et al. Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol. 2005;96:314–9.

    PubMed  Article  CAS  Google Scholar 

  30. Rauvala M, Aglund K, Puistola U, et al. Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer. 2006;16:1297–302.

    PubMed  Article  CAS  Google Scholar 

  31. Sheu BC, Lien HC, Ho HN, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 2003;63:6537–42.

    PubMed  CAS  Google Scholar 

  32. Sheu BC, Hsu SM, Ho HN, et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001;61:237–42.

    PubMed  CAS  Google Scholar 

  33. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem. 1996;271:14657–60.

    PubMed  Article  CAS  Google Scholar 

Download references

Conflict of interest

We declared no conflict of interest.

Author information

Affiliations

  1. Department of Gynaecology and Obstetrics, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, China

    Yi Li, Beilei Zhang, Yuanqing Yao & Guowu Yin

  2. Department of General Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, China

    Tao Wu

Authors
  1. Yi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beilei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuanqing Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guowu Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yuanqing Yao or Guowu Yin.

Additional information

Yi Li and Tao Wu contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Li, Y., Wu, T., Zhang, B. et al. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med Oncol 29, 3394–3399 (2012). https://doi.org/10.1007/s12032-012-0283-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0283-z

Keywords

  • MMP-9
  • Cervical cancer
  • Immunohistochemistry
  • Prognosis